Details

Autor(en) / Beteiligte

• Lanzolla, G.
• Maglionico, M. N.
• Comi, S.
• Menconi, F.
• Piaggi, P.
• Posarelli, C.
• Figus, M.
• Marcocci, C.
• Marinò, M.

Titel

Sirolimus as a second-line treatment for Graves’ orbitopathy

Ist Teil von

• Journal of endocrinological investigation, 2022-11, Vol.45 (11), p.2171-2180

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2022

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• Objectives A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line treatment for moderate-to-severe, active GO compared with methylprednisolone. Methods Data from consecutive patients given sirolimus (2 mg orally on first day, followed by 0.5 mg/day for 12 weeks) or methylprednisolone [500 mg iv/weekly (6 weeks), 250 mg/weekly (6 weeks)] as a second-line treatment were collected and compared. Primary objective: overall GO outcome at 24 weeks, based on a composite evaluation. Secondary objectives at 24 weeks: (1) improvement in quality of life, evaluated using a specific uestionnaire (GO-QoL); (2) reduction in proptosis; (3) reduction in the clinical activity score (CAS); (4) improvement of eye ductions; and (5) reduction in eyelid aperture. Results Data from 30 patients (15 per group) treated between January 15, 2020, and June 15, 2021, were analysed. Proportion of GO responders (primary outcome) at 24 weeks was significantly greater in sirolimus group compared with methylprednisolone group (86.6% vs 26.6%; OR: 17.8; 95% CI from 2.7 to 116.8; P  = 0.0026). GO-quality of life (GO-QoL) score was greater in sirolimus group. Proportion of proptosis responders was greater in sirolimus group, as well as proportion of clinical activity score (CAS) responders. No serious adverse events were observed, with no differences between groups. Conclusions Sirolimus seems to be an effective second-line treatment for GO. Further randomized clinical trials are needed to confirm our observations.